These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1904359)

  • 1. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice.
    Lynch DH; Miller RE
    Eur J Immunol; 1991 Jun; 21(6):1403-10. PubMed ID: 1904359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes.
    Lynch DH; Namen AE; Miller RE
    Eur J Immunol; 1991 Dec; 21(12):2977-85. PubMed ID: 1684156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
    Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM
    J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The augmenting effect of OK432-stimulated B cells on the in vitro generation of anti-tumor cytotoxic T lymphocytes from tumor-draining lymph node cells: the possible role of interleukin-12.
    Shinomiya Y; Harada M; Tamada K; Kurosawa S; Okamoto T; Terao H; Takenoyama M; Ito O; Hirashima C; Li T; Shirakusa T; Nomoto K
    In Vivo; 1997; 11(1):1-8. PubMed ID: 9067765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system.
    Evans R; Duffy TM; Kamdar SJ
    Eur J Immunol; 1991 Aug; 21(8):1815-9. PubMed ID: 1907916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
    Ellenhorn JD; Schreiber H; Bluestone JA
    J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
    Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
    Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.